The company also received FDA clearance for the Inogen Rove 6, which launched in July 2023, marking the first POC with an eight-year expected service life, a feature also extended to the Inogen ...

It is doubtless a positive to see that the Inogen, Inc. ( NASDAQ:INGN ) share price has gained some 38% in the last... INGN and Yuwell collaborate to expand and enhance Inogen's innovation ...

Inogen, Inc. INGN announced preliminary revenues ... are estimated to be between $334.5 million and $335.5 million, up 6% from the comparable 2023 period. The Zacks Consensus Estimate of $329.5 ...

Needham analyst Michael Matson has maintained their neutral stance on INGN stock, giving a Hold rating on January 14.Invest with Confidence: ...

Inogen (INGN) announced it has entered into a strategic collaboration with Jiangsu Yuyue Medical Equipment & Supply. The strategic collaboration is expected to broaden Inogen’s product portfolio ...

Inogen, Inc. INGN recently announced a strategic collaboration with Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.

Inogen, Inc. INGN announced preliminary revenues for the fourth ... full-year 2024 total revenues are estimated to be between $334.5 million and $335.5 million, up 6% from the comparable 2023 period.